MBP

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	15

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 15 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002180-33-PL (EUCTR)	16/11/2016	14/07/2016	Multiple sclerosis therapy with transdermal myelin peptide stimulation.	Multiple sclerosis therapy with transdermal myelin peptide stimulation.	relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10 ...	Product Name: SMderpept INN or Proposed INN: PLP peptide INN or Proposed INN: MBPpeptide INN or Propose ...	Centrum Neurologii Krzysztof Selmaj	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	220	Phase 2	Poland
2	EUCTR2004-002571-16-GB (EUCTR)	29/06/2007	22/02/2005	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	Secondary progressive multiple sclerosis MedDRA version: 8.1;Level: LLT;Classification code 10063400 ...	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 INN or Proposed INN: Dirucotide acetate O ...	BioMS Technology Corp	NULL	Not Recruiting			Female: yes Male: yes	553		Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden
3	NCT00468611 (ClinicalTrials.gov)	June 2007	1/5/2007	Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis	A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 ...	Multiple Sclerosis, Secondary Progressive	Drug: MBP8298	BioMS Technology Corp.	NULL	Terminated	18 Years	65 Years	Both	510	Phase 3	United States
4	NCT00870155 (ClinicalTrials.gov)	February 2007	26/3/2009	A Study for Patients With Multiple Sclerosis	An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Pro ...	Secondary Progressive Multiple Sclerosis	Drug: dirucotide	Eli Lilly and Company	BioMS Technology Corp.	Terminated	18 Years	65 Years	Both	546	Phase 2/Phase 3	Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom
5	NCT00869986 (ClinicalTrials.gov)	November 2006	24/3/2009	A Study for Patients With Relapsing Remitting Multiple Sclerosis	A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 ...	Relapsing Remitting Multiple Sclerosis	Drug: dirucotide;Drug: placebo	Eli Lilly and Company	BioMS Technology Corp.	Completed	18 Years	50 Years	Both	218	Phase 2/Phase 3	Bulgaria;Poland;Russian Federation;Serbia;Slovakia;Ukraine
6	EUCTR2004-002571-16-EE (EUCTR)	28/09/2006	09/06/2006	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	Secondary progressive multiple sclerosis MedDRA version: 8.1;Level: LLT;Classification code 10063400 ...	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 INN or Proposed INN: Dirucotide acetate O ...	BioMS Technology Corp	NULL	Not Recruiting			Female: yes Male: yes	553		Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
7	EUCTR2004-002571-16-LT (EUCTR)	27/09/2006	01/08/2006	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	Secondary progressive multiple sclerosis MedDRA version: 8.1;Level: LLT;Classification code 10063400 ...	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 INN or Proposed INN: Not Known Other desc ...	BioMS Technology Corp	NULL	Not Recruiting			Female: yes Male: yes	553		Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Sweden;Lithuania
8	EUCTR2006-001947-70-SK (EUCTR)	14/09/2006	08/08/2006	A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of M ...	A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of M ...	Relapsing Remitting Multiple Sclerosis	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 Other descriptive name: MBP8298 Syntheti ...	BioMS Technology Corp.	NULL	Not Recruiting			Female: yes Male: yes	215	Phase 2	Slovakia
9	EUCTR2004-002571-16-LV (EUCTR)	21/07/2006	24/08/2006	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	Secondary progressive multiple sclerosis	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 INN or Proposed INN: Not known Other desc ...	BioMS Technology Corp	NULL	Not Recruiting			Female: yes Male: yes	553		Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
10	EUCTR2004-002571-16-ES (EUCTR)	20/07/2006	09/06/2006	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 ...	Secondary progressive multiple sclerosis	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 Other descriptive name: MBP8298 Syntheti ...	BioMS Technology Corp	NULL	Not Recruiting			Female: yes Male: yes	553	Phase 2;Phase 3	Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden

First Previous1 2Next Last